Manufacturing of RCA-free adenoviral vectors
On demand

Manufacturing of RCA-free adenoviral vectors

Tuesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Manufacturing of RCA-free adenoviral vectors

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

Adenoviral vectors are frequently used as delivery tools for vaccines and gene therapy applications. In most cases, replication-incompetent adenoviruses (RCA) are employed, which, once they have infected a target cell, cannot spread further in a patient‘s body. In such applications, regulatory guidelines require that the formation of RCA during the production process must be minimized. Since the risk of RCA occurrence depends on the adenoviral vector and the cell line used for virus stock generation and manufacturing, the choice of an appropriate cell line and production platform is a critical decision. Ideally, it should allow, among other things, simple, scalable and GMP-compliant production of adenoviral vectors at high titers and without the risk of RCA formation.

Here we present the CAP® Ad platform, a production platform for adenoviral vectors based on CAP® cells and specifically designed to address these requirements. CAP® cells can be cultivated in all common bioreactors using serum-free, chemically defined media. They grow to high densities as single cells in suspension and support high titer, RCA-free adenoviral vector production. The webinar will provide further background information on the CAP® Ad production platform and typical process flows used for adenoviral vector manufacturing at industrial scale.

  • Impact of the adenovirus biology on its use as a viral vector
  • Uses of adenoviral vectors for various medical applications
  • Importance of avoiding RCA in the manufacturing process
  • Achieving industrial scale adenoviral vector production using the CAP® Ad platform
Nico Scheer
Nico Scheer
Senior Consultant Business Development at CEVEC, now part of Cytiva

Dr. Nico Scheer has >20 years of experience in research and business development in the life science industry as well as a strong scientific background in molecular biology, immunology and viral vector technologies. He published several peer reviewed scientific articles and book chapters in different fields of research. Dr. Scheer holds a professorship in Molecular Biology at FH Aachen University of Applied Sciences and supports CEVEC Pharmaceuticals GmbH as Senior Consultant Business Development.